Bedaquiline or delamanid for rifampin-resistant tuberculosis?

Lancet Respir Med. 2017 Oct;5(10):772-774. doi: 10.1016/S2213-2600(17)30309-0. Epub 2017 Sep 5.

Authors

Erica Lessem¹, Vivian Cox², Jennifer Furin³

Affiliations

¹ Treatment Action Group, TB/HIV Project, New York, NY, USA.
² Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
³ Harvard Medical School, Department of Global Health and Social Medicine, Boston, MA, USA. Electronic address: jenniferfurin@gmail.com.

PMID: 28887015
DOI: 10.1016/S2213-2600(17)30309-0

No abstract available

MeSH terms

Antitubercular Agents / therapeutic use*
Diarylquinolines / therapeutic use*
Drug Resistance, Bacterial / drug effects
Humans
Mycobacterium tuberculosis / drug effects
Nitroimidazoles / therapeutic use*
Oxazoles / therapeutic use*
Rifampin / pharmacology*
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Antitubercular Agents
Diarylquinolines
Nitroimidazoles
OPC-67683
Oxazoles
bedaquiline
Rifampin